-
公开(公告)号：EP1353937A2
公开(公告)日：2003-10-22
申请号：EP01994329.9
申请日：2001-12-31
发明人： HAGAI, Yocheved , LAZAROVITS, Janette , GUY, Rachel , LIPSCHITZ, Orly , SZANTON, Esther , LEVANON, Avigdor , PLAKSIN, Daniel , PERETZ, Tuvia
IPC分类号： C07H21/04 , C07K5/00 , A61K39/395 , C12N15/00 , G01N33/53
CPC分类号： C07K14/472 , A61K38/00
摘要： The present invention is directed to a peptide or polypeptide comprising an Fv molecule, a construct thereof, a fragment of either, or a construct of a fragment having enhanced binding characteristics so as to bind selectively and/or specifically to a target cell in favor of other cells, wherein the binding selectivity or specificity is primarily determined by a first hypervariable region, and wherein the Fv is a scFv or a dsFv, and optionally having one or more tags. The enhanced binding is directed to a substantially exposed and/or over-expressed binding site on or in a target comprising a cell in favor of other cells on or in which the binding site is not substantially available and/or expressed. The invention is further directed to a method for isolating such peptides and polypeptides from a phage display library and to the nucleic acid molecules encoding them. The invention provides for a pharmaceutical composition comprising the peptide or polypeptide and kits for diagnosis and treatment of disease, specifically cancer, most specifically acute myeloid leukemia.
-
2.发明授权
公开(公告)号：EP0693925B1
公开(公告)日：2002-02-13
申请号：EP94914102.2
申请日：1994-04-08
申请人： BIO-TECHNOLOGY GENERAL CORPORATION , YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
发明人： WERBER, Moshe M. , ZEELON, Elisha P. , LEVANON, Avigdor , GUY, Rachel , GOLDLUST, Arie , RIGBI, Meir , PANET, Amos , FISCHER, Meir
CPC分类号： C07K14/815 , A61K38/00 , C07K16/38
摘要： The present invention provides a recombinant polypeptide having the amino acid sequence X-tyr - gly where tyr - gly is identical to the sequence shown in Figure 10, and wherein X is methionine or absent and wherein asn may be substituted by pro. The invention further provides a method of producing the polypeptide which comprises transforming a host cell with an expression plasmid encoding the polypeptide, culturing the transformed host cell so that the cell produces the polypeptide encoded by the plasmid, and a method of recovering the polypeptide so produced.
-
3.发明授权Verwendung von Mangan-Superoxiddismutase (Mn-SOD) zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen in niedriger Dosierung 失效锰超氧化物歧化酶的使用（Mn-SOD的）用于制备药物的用于以低剂量治疗的疾病
公开(公告)号：EP0587055B1
公开(公告)日：2001-12-05
申请号：EP93114113.9
申请日：1993-09-03
IPC分类号： A61K38/44
CPC分类号： A61K38/446
-
4.发明公开
公开(公告)号：EP1100901A1
公开(公告)日：2001-05-23
申请号：EP99935028.3
申请日：1999-07-29
发明人： EISENBACH, Lea , CARMON, Lior , TIROSH, Boaz , BAR-HAIM, Erez , PAZ, Adrian , FRIDKIN, Matityahu , FITZER-ATTAS, Cheryl
IPC分类号： C12N15/12 , C07K14/47 , C07K14/705 , C12N9/16 , C12N9/64 , A61K38/17 , A61K38/46 , A61K38/47 , C12N15/55 , C12N15/57 , C12N5/08
CPC分类号： C12N9/6445 , A61K39/00 , A61K48/00 , C07K14/47 , C07K14/4727 , C07K14/705 , C12N9/16
摘要： The present invention relates to tumor associated antigen (TAA) peptides and to the use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.
-
5.发明授权Growth hormone analogs, pharmaceutical and veterinary compositions containing said analogs and methods for production thereof 失效生长激素类似物，药学和兽医学组合物含有它们和它们的制备方法
公开(公告)号：EP0319049B1
公开(公告)日：1996-04-17
申请号：EP88121246.8
申请日：1984-07-03
-
6.发明公开FIBRIN BINDING DOMAIN POLYPEPTIDES AND USES AND METHODS OF PRODUCING SAME 失效多肽，FIBRINBINDUNGSDOMÄNE，使用和方法ITS。
公开(公告)号：EP0651799A1
公开(公告)日：1995-05-10
申请号：EP91911888.0
申请日：1991-05-21
发明人： VOGEL, Tikva , LEVANON, Avigdor , WERBER, Moshe , GUY, Rachel , PANET, Amos , HARTMAN, Jacob , SHAKED, Hadassa
IPC分类号： A61K38 , A61K47 , A61K49 , A61K51 , A61M25 , C07K1 , C07K7 , C07K14 , C07K19 , C12N1 , C12N9 , C12N15 , C12P21 , C12Q1 , C12R1
CPC分类号： A61K49/0008 , A61K38/00 , A61K47/6415 , A61K49/0002 , A61K49/0004 , A61K51/082 , A61K51/088 , A61K2123/00 , A61M25/0045 , C07K1/1133 , C07K7/06 , C07K14/3153 , C07K14/78 , C07K19/00 , C07K2319/00 , C07K2319/33
摘要： This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occuring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occuring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides. The invention also provides for purified polypeptides substantially free of other substances of human origin which have an amino acid sequence substantially present in the fibrin binding domain of naturally-occuring human fibronectin and which are capable of binding to fibrin.
-
公开(公告)号：EP0408742B1
公开(公告)日：1994-09-28
申请号：EP90907882.6
申请日：1990-02-07
发明人： EVEN-CHEN, Zeev
IPC分类号： A61K39/29
CPC分类号： C07K14/005 , C12N15/85 , C12N2730/10122
摘要： Processes are provided for producing purified, hepatitis B surface antigen particles in mammalian cells which comprise culturing mammalian cells which produce the particles in a culture medium supplemented with a serum free of high molecular weight contaminant proteins and recovering the purified, hepatitis B surface antigen particles. Removal of molecules having a molecular weight greater than about 3 x 105 daltons by prefractionation, for example, allows cells to be grown in culture media containing high levels of fetal calf serum, removes high molecular weight contaminant proteins which may be inhibitory to cell growth and simplifies purification of HBsAg since high molecular weight contaminant proteins are the major contaminants removed by purification processes.
-
8.发明公开EXPRESSION OF ENZYMATICALLY ACTIVE RECOMBINANT HUMAN ACETYLCHOLINESTERASE AND USES THEREOF 失效表达酶活性重组人乙酰胆碱酯酶及其应用。
公开(公告)号：EP0591472A1
公开(公告)日：1994-04-13
申请号：EP92918513.0
申请日：1992-07-22
发明人： FISHER, Meir
CPC分类号： C12N9/18 , A61K38/00 , C12N15/70 , C12Q1/46 , C12Q1/6886 , C12Q2600/158 , G01N33/581
摘要： Acétylcholinestérase humaine de recombinaison, non glycosylée, active sur le plan enzymatique, renfermant au moins un polypeptide caractérisé par une séquence d'acides aminés essentiellement identiques à la séquence d'acides aminés de l'acétylcholinestérase humaine ne se produisant pas naturellement. L'invention porte en outre sur une acétylcholinestérase humaine monomère recombinée, active sur le plan enzymatique, renfermant un polypeptide caractérisé par une séquence d'acides aminés dans laquelle la sérine est remplacée par cis 611 dans la séquence d'acétylcholinestérase humaine non naturelle (position 580 dans le polypeptide mature) et sur une acétylcholinestérase humaine de recombinaison, active sur le plan enzymatique, renfermant au moins un polypeptide caractérisé par la présence d'une méthionine de l'extrémité terminale N de la séquence d'acides aminés de l'acétylcholinestérase humaine naturelle. L'invention porte également sur des méthodes thérapeutiques et diagnostiques mettant en oeuvre cette acétylcholinestérase de recombinaison active sur le plan enzymatique.
-
9.发明公开IMPROVED METHOD FOR PURIFICATION OF RECOMBINANT COPPER/ZINC (CU-ZN) SUPEROXIDE DISMUTASE FROM BACTERIA OR EUCARYOTIC CELLS 失效改进方法清洁重组铜/锌（Cu-Zn类）超氧化物歧化酶从细菌或真核细胞。
公开(公告)号：EP0499621A1
公开(公告)日：1992-08-26
申请号：EP90917624.0
申请日：1990-11-07
发明人： BARTFELD, Daniel , LIFSHITZ, Ruth , HADARY, Dany
IPC分类号： C12N9
CPC分类号： C12N9/0089
摘要： Un procédé permet de récupérer une solution contenant de la dismutase purifiée enzymatiquement active de superoxyde de Cu-Zn ou un analogue polypeptidique de celle-ci ayant essentiellement la même séquence d'acides aminés et la même activité biologique de la dismutase de superoxyde de Cu-Zn naturelle, à partir d'une composition qui comprend des cellules contenant de la dismutase de superoxyde de Cu-Zn ou un analogue polypeptidique de celle-ci. Ce procédé permet en outre d'augmenter le rendement d'extraction des solutions ayant une concentration accrue de l'isoforme b d'un analogue polypeptidique enzymatiquement actif de la dismutase de superoxyde de Cu-Zn à partir d'une composition qui comprend des cellules contenant des isoformes a, b et c de l'analogue polypeptidique.
-
10.发明授权Plasmids containing lambda Pl promoter, and engineered restriction site for convenient replacement of ribosomal binding site, hosts containing the plasmids and related methods 失效含有LAMBDA PL促进剂的PLASMIDS和用于方便更换RIBOSOMAL结合位点的工程限制站点，含有PLASMIDS的宿主和相关方法
公开(公告)号：EP0173280B1
公开(公告)日：1992-08-12
申请号：EP85110683.1
申请日：1985-08-26
发明人： Aviv, Haim , Bartfeld, Daniel , Gorecki, Marian , Hartman, Jacob R. , Kanner, Dov , Levanon, Avigdor , Locker-Giladi, Hilla , Oppenheim, Amos B.
CPC分类号： C12N9/0089 , A23K20/168 , A61K38/446 , C07K14/61 , C07K14/775 , C12N15/69 , C12N15/73
-
-
-
-
-
-
-
-
-
搜索结果
57 条记录 (耗时 0.028 秒)
